Glucotrack, Inc. 8K

Lōkahi Therapeutics, a subsidiary of Glucotrack, is advancing LT-100 toward clinical evaluation as a single subcutaneous injection instead of up to 15 intradermal injections, targeting trial initiation as early as Q4 2026.

On July 29, 2026, Lōkahi Therapeutics Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), announced that following a May 2026 FDA Type C meeting and completion of a nonclinical minipig study comparing subcutaneous versus intradermal administration of its LT-100 product candidate, it is advancing a development strategy to transition LT-100 from up to 15 intradermal injections per treatment visit to a single subcutaneous injection. The nonclinical data on systemic exposure are being used to support a planned clinical evaluation of the single-injection approach, which the company anticipates could begin as early as the fourth quarter of 2026 with an initial data readout potentially in the first half of 2027. Management highlighted that simplifying administration while maintaining systemic exposure consistent with prior clinical experience is a key development objective and is proceeding with ongoing development and regulatory activities to enable this next clinical phase.

Filing Facts

CIK

1506983

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-035503

Alert Tier

6